Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 1, 2013, Pages 203-205

  Stegeman, B H ^a   Raps, M ^a   Helmerhorst, F M ^a   Vos, H L ^a   Van Vliet, H A A M ^a,b   Rosendaal, F R ^a   Van Hylckama Vlieg, A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BIOLOGICAL MARKER; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN;

ADULT; CARDIOVASCULAR RISK; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LETTER; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; VEIN PUNCTURE; VEIN THROMBOSIS;

EID: 84873025714     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12054     Document Type: Letter

References (7)

1. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002; 81: 482-90.
2. van Vliet HA, Frolich M, Thomassen MCLGD, Doggen CJ, Rosendaal FR, Rosing J, Helmerhorst FM. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005; 20: 563-8.
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
4. Fotherby K. A metabolic assessment of different oral contraceptives. J Obstet Gynaecol 1983; 3: S77-82.
5. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187-96.
6. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
7. Stadel BV, Sternthal PM, Schlesselman JJ, Douglas MB, Hall WD, Kaul, Ahluwalia B. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril 1980; 33: 257-60.